Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden adds Ozempic to list for Medicare price negotiationIn one of its last actions, the Biden ...

Apple stock rises after falling Thursday by the most since August, Alphabet stock is up after the Supreme Court upholds a ban on TikTok, and Qorvo stock jumps after activist Starboard Value amasses a ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.

Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...

Wall Street started higher ahead of Trump's inauguration on Monday. Investors expect a flurry of executive orders, including ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

BofA Securities maintained an Underperform rating on shares of Hims & Hers Health, Inc. (NYSE:HIMS) with a steady price ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

After Novo Nordisk (NVO) reported results from its Phase 3b STEP UP trial, which showed that adults with obesity achieved a 20.7% weight loss ...